Skip to main content

Table 3 Unadjusted adherence to quality-of-care indicators by payer status (%)a

From: The effect of low insurance reimbursement on quality of care for non-small cell lung cancer in China: a comprehensive study covering diagnosis, treatment, and outcomes

Indicators (No. eligible) Overall High reimbursement rate Low reimbursement rate P
ECT and brain MRI or CT (752) 57.58 60.92 54.33 0.0677
PFTs (1909) 81.72 76.65 87.85 <.0001
EGFR mutation test (453) 3.31 4.76 1.49 0.0533
ACT (938) 48.84 52.24 44.69 0.0484
Recommended for ACT (533) 44.09 48.26 37.96 0.0187
PORT (1376) 1.82 2.88 0.49 0.0010
ACT response assessment (659) 53.41 59.41 47.02 0.0014
First-line chemotherapy (977) 69.54 68.60 70.56 0.5087
Lobectomy (559) 84.97 83.18 87.61 0.1505
Surgical resection (1434) 96.16 96.85 95.32 0.1342
Combination therapy (747) 61.58 60.87 62.27 0.6942
Complications (1916) 5.53 5.42 5.66 0.8181
Metastases (1916) 9.65 10.75 8.09 0.0488
In-hospital mortality (2643) 2.65 3.66 1.47 0.0005
2-year mortality rate (825) 21.45 19.72 22.80 0.2862
total length of hospital stay (2643) 21.11 ± 16.76 21.30 ± 16.56 20.89 ± 17.00 0.0672
preoperative length of hospital stay (1916) 7.56 ± 6.55 7.84 ± 6.27 7.22 ± 6.86 <.0001
  1. aDiscrete variables were expressed as counts (%) and continuous variables were expressed as a mean ± range. Abbreviations: ECT and brain MRI or CT skeletal scintigraphy and brain magnetic resonance imaging or computed tomography, PFTS pulmonary function tests, EGFR epidermal growth factor receptor, ACT adjuvant chemotherapy, PORT postoperative radiation therapy